Methods of treating emesis using growth hormone secretagogues
A method of treating emesis with growth hormone secretagogues, particularly ipamorelin.
1. A method of treating emesis induced by cancer chemotherapy or post-operative nausea and vomiting in a subject comprising administering to a subject in need of such treatment, via intravenous injection, a treatment effective amount of a compound of structure XIV, or a pharmaceutically acceptable salt thereof:
2. The method of claim 1 , wherein the compound is administered at an amount of from 1 to 150 mg/day.
3. The method of claim 2 , wherein the compound is administered at an amount of from 10 to 100 mg/day.
4. The method of claim 3 , wherein the compound is administered at an amount of about 50 mg/day.
5. The method of claim 1 , wherein the subject is receiving cancer chemotherapy.
6. The method of claim 1 , wherein said treatment is defined by an increase in the period of latency of an emetic episode in a subject.
7. The method of claim 1 , wherein said treatment is defined based on a reduction in the number of episodes of nausea and vomiting.
8. The method of claim 1 , wherein said emesis is post-operative nausea and vomiting.
9. The method of claim 1 , wherein said emesis is induced by cancer chemotherapy.
10. The method of claim 1 wherein the compound is administered in an amount of about: 200 mcg, 300 mcg, 400 mcg, 500 mcg, 1 mg, 1.25 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, or 50 mg.
11. The method of claim 10 , wherein the compound is administered in an amount of about: 1 mg, 1.25 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5 mg, or 10 mg.
12. A method of increasing the period of latency in a subject prior to an episode of emesis, wherein the episode of emesis is induced by cancer chemotherapy, or wherein the episode of emesis is post-operative, comprising administering to a subject in need of such treatment, via intravenous injection, a treatment effective amount of a compound of structure XIV, or a pharmaceutically acceptable salt thereof:
13. The method of claim 12 , wherein the compound is administered in an amount of from 1 mg to 150 mg.
14. The method of claim 12 , wherein the compound is administered in an amount of from 10 mg to 100 mg.
15. The method of claim 12 wherein the compound is administered in an amount of about: 200 mcg, 300 mcg, 400 mcg, 500 mcg, 1 mg, 1.25 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, or 50 mg.
16. The method of claim 15 , wherein the compound is administered in an amount of about: 1 mg, 1.25 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5 mg, or 10 mg.
17. The method of claim 12 , wherein said emesis is post-operative.
18. The method of claim 12 , wherein said emesis is induced by cancer chemotherapy.
19. A method of reducing the number of episodes of retching in a subject induced by cancer chemotherapy or post-operative nausea and vomiting, comprising administering to a subject in need of such treatment, via intravenous injection, a treatment effective amount of a compound of structure XIV, or a pharmaceutically acceptable salt thereof:
20. The method of claim 19 , wherein the compound is administered in an amount of from 1 mg to 150 mg.
21. The method of claim 19 , wherein the compound is administered in an amount of from 10 mg to 100 mg.
22. The method of claim 19 wherein the compound is administered in an amount of about: 200 mcg, 300 mcg, 400 mcg, 500 mcg, 1 mg, 1.25 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, or 50 mg.
23. The method of claim 22 , wherein the compound is administered in an amount of about: 1 mg, 1.25 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5 mg, or 10 mg.
24. The method of claim 19 , wherein said retching is induced by post-operative nausea and vomiting.
25. The method of claim 19 , wherein said retching is induced by induced by cancer chemotherapy.